Abstract
Background Despite recent efforts, a single factor underlying the gut microbiota dysbiosis in intestinal diseases is not identified. We hypothesized that compromised intestinal barrier (CIB) could lead to increased host-derived contents including human cells in the gut, change its physio-metabolic properties, and globally alter gut microbiota and their metabolic capacities.
Results Consistently, we found human DNA contents (HDCs), calculated as the percentage of metagenomic sequencing reads mapped to the human genome, were significantly elevated in colorectal cancer (CRC) patients; HDC correlated with microbial- and metabolic-pathway-biomarkers of CRC, and was the most important contributor to patient stratification. We found similar results in Crohn’s disease (CD); additionally, patients treated with diet and drug intervention showed reduced HDC levels over time, and were accompanied by reversing changes of many CD-signature species.
Conclusions Our results suggested that host-derived contents may have greater impact on gut microbiota than previously anticipated, and CIB could be an ideal treatment target that could reverse dysbiosis globally and precisely.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly supported by National Key Research and Development Program of China 2018YFC0910502 (to W.H.C.), National Natural Science Foundation of China (61932008, 61772368, 61572363), National Key R&D Program of China (2018YFC0910500), Natural Science Foundation of Shanghai (17ZR1445600), Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and ZJLab.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Emails: Puzi Jiang: puzjiang{at}hust.edu.cn, Senying Lai: 2105028906{at}qq.com, Sicheng Wu: wu_sicheng{at}hust.edu.cn, Xiushan Yin: xiushanyin{at}gmail.com, Jingjing Zhang: zhangciara2018{at}163.com, Xing-Ming Zhao: xmzhao{at}fudan.edu.cn, Shun-Qing Xu: xust{at}hust.edu.cn, Wei-Hua Chen: weihuachen{at}hust.edu.cn
Data Availability
all data are publicly available. the corresponding links to public database have been included in the manuscript.
List of abbreviations
- CIB
- Compromised intestinal barrier
- HDC
- Human DNA content
- CRC
- Colorectal cancer
- CD
- Crohn’s disease
- IBD
- Inflammatory bowel disease
- LODO
- Leave-one-dataset-out
- QPCR
- Quantitative polymerase chain reaction
- AUC
- Area under the receiver-operating characteristics curve
